ZymoGenetics
|
Zymogenetics, Inc. is focused on the discovery, development, manufacture and commercialization of therapeutic proteins for the treatment of human diseases. The Company's therapeutic focus is in the areas of hemostasis, inflammatory and autoimmune diseases, cancer and viral infections. Its first internally developed product candidate, RECOTHROM Thrombin ((also referred to as rThrombin), topical (Recombinant), was approved by the United States Food and Drug Administration (FDA) on January 17, 2008, for use as a topical hemostat to control moderate bleeding during surgical procedures and is being marketed in the United States.
(Source: 10-K)
More from Zoominfo » |
ZymoGenetics injunction lifted
A federal court judge in Tennessee has lifted temporary restraining orders that barred ZymoGenetics from making certain claims in its marketing of the blood-clotting agent Recothrom, the Seattle-based biotechnology company said Friday.
From Seattle Times - 4 days ago
ZymoGenetics shrinks 3Q loss as revenue rises
Biotechnology company ZymoGenetics Inc. said Thursday it cut its third-quarter loss by more than half, as sales of its drug Recothrom improved and research and development costs decreased.
From AP via Yahoo! Finance - 5 days ago
ZymoGenetics Reports Third Quarter 2009 Financial Results
SEATTLE----ZymoGenetics, Inc. today reported improved financial results for the third quarter ended September 30, 2009. The company’s net loss for the quarter declined substantially to $11.4 million, or $0.17 per share, from $28.8 million, or $0.42 per share, for the third quarter of 2008.
From Business Wire via Yahoo! Finance - 5 days ago
More news from Yahoo! News
|
|
|
